Coronavirus Update: iSPOCs, Fake Drugs & Data Protection Concerns

In addition to our daily in-depth coverage of key events relating to the COVID-19 pandemic, we’re bringing you a periodic round-up of other developments. This edition covers events at EU and member state level, as well as initiatives by international regulators.

Covid19_Stamp_WorldMap
National actions continue in an effort to stem the spread of the coronavirus • Source: Shutterstock

With the pandemic continuing its deadly spread, individual countries are taking steps to address the growing number of COVID-related drug shortages, and regulator-industry cooperation is the order of the day. The increased risk of fake and unlicensed medical products has been highlighted, as have concerns about the data protection aspects of using technology to understand the spread of the coronavirus.

Supplies of vital medicines used for treating hospitalized COVID-19 patients are beginning to run dry in some EU member states. Particularly hard hit are anesthetics, antibiotics and muscle relaxants used in intensive care units, as well as medicines used off-label or in clinical trials for treating the coronavirus. France, for example, recently said it was allowing the import of propofol and has even given the go-ahead for veterinary versions of the anesthetic to be used in humans

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Europe

More from Geography